Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist

More on GLP1R

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026

• Retatrutide reduces weight and pain in adults with obesity

  The New England Journal of Medicine · 4 Oct 2026

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026

• Genetically proxied GIP pathway links to lower fracture risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026